TY - JOUR
T1 - Iron overload in β-thalassemia intermedia
T2 - An emerging concern
AU - Musallam, Khaled M.
AU - Cappellini, Maria D.
AU - Taher, Ali T.
PY - 2013/5
Y1 - 2013/5
N2 - Purpose of Review: The aim is to overview recent evidence on consequences, assessment, and management of iron overload in transfusion-independent patients with β-thalassemia intermedia. Recent Findings: Despite their transfusion-independence, β-thalassemia intermedia patients can still accumulate iron due to increased intestinal absorption. Recent observational studies show that iron burden in this group of patients can ultimately reach considerably high thresholds, and leads to a variety of serious morbidities involving the liver, endocrine glands, and arguably the vascular system. The diagnosis of iron overload in this patient population can follow established guidelines from β-thalassemia major patients, although with careful interpretation of spot serum ferritin levels. Data from a recent randomized clinical trial demonstrated the efficacy and safety of iron chelation therapy in decreasing liver iron concentration in this group of patients, which may ultimately help in reducing morbidity risk. Summary: Iron overload in transfusion-independent patients with β-thalassemia intermedia deserves careful attention, and prompt diagnosis and management are recommended.
AB - Purpose of Review: The aim is to overview recent evidence on consequences, assessment, and management of iron overload in transfusion-independent patients with β-thalassemia intermedia. Recent Findings: Despite their transfusion-independence, β-thalassemia intermedia patients can still accumulate iron due to increased intestinal absorption. Recent observational studies show that iron burden in this group of patients can ultimately reach considerably high thresholds, and leads to a variety of serious morbidities involving the liver, endocrine glands, and arguably the vascular system. The diagnosis of iron overload in this patient population can follow established guidelines from β-thalassemia major patients, although with careful interpretation of spot serum ferritin levels. Data from a recent randomized clinical trial demonstrated the efficacy and safety of iron chelation therapy in decreasing liver iron concentration in this group of patients, which may ultimately help in reducing morbidity risk. Summary: Iron overload in transfusion-independent patients with β-thalassemia intermedia deserves careful attention, and prompt diagnosis and management are recommended.
KW - assessment
KW - liver iron concentration
KW - management
KW - morbidity
UR - http://www.scopus.com/inward/record.url?scp=84876298371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876298371&partnerID=8YFLogxK
U2 - 10.1097/MOH.0b013e32835f5a5c
DO - 10.1097/MOH.0b013e32835f5a5c
M3 - Article
C2 - 23426199
AN - SCOPUS:84876298371
VL - 20
SP - 187
EP - 192
JO - Current Opinion in Hematology
JF - Current Opinion in Hematology
SN - 1065-6251
IS - 3
ER -